Biocon Biologics and Viatris launch their third oncology biosimilar in Canada
Abevmy, co-developed by Biocon Biologics and Viatris, is a biosimilar to Roche’s Avastin (Bevacizumab) and has been approved by Health Canada across four oncology indications.
Source: businesstoday.in